PROCEPT BioRobotics (PRCT)

The company’s key platform is the AquaBeam Robotic System, which enables Aquablation therapy. The system combines real-time imaging, robotic planning, and a high-velocity waterjet to remove prostate tissue while helping surgeons preserve important anatomy. PROCEPT also markets the HYDROS Robotic System, an additional image-guided robotic platform intended to expand and improve its urology offering. Its business model includes the placement of robotic systems and the sale of associated disposable products used in procedures.

PROCEPT sells primarily to hospitals and surgical providers, and most of its revenue is generated in the United States, although it also operates in selected international markets. Adoption depends on surgeon training, hospital capital spending, clinical outcomes, reimbursement, and the ability to demonstrate advantages over established BPH treatments such as transurethral resection of the prostate, laser procedures, and medication.

What sets PROCEPT apart is its narrow specialization in robotic urology rather than a broad surgical robotics portfolio. By concentrating on BPH, the company targets a large procedure market with a technology designed to offer precise tissue removal, reproducible planning, and a minimally invasive alternative for patients whose symptoms require procedural treatment.